2026 Buying Tips,SRP

SRP-5051, also known by its investigational name vesleteplirsen, represents a significant area of research within the field of Duchenne Muscular Dystrophy (DMD). This peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO) was developed by Sarepta Therapeutics with the goal of addressing the underlying genetic cause of DMD by targeting exon 51 skipping. Understanding the development, mechanism, and clinical journey of SRP-5051 is crucial for patients, caregivers, and researchers involved in the fight against this debilitating genetic disorder.

At its core, SRP-5051 is a new generation antisense oligonucleotide designed to interact with the dystrophin gene. DMD is characterized by mutations in the dystrophin gene, leading to a lack of functional dystrophin protein, which is essential for muscle integrity. SRP-5051 was engineered to bind to exon 51 of the dystrophin pre-messenger RNA (pre-mRNA). By binding to this specific exon, SRP-5051 aims to promote its exclusion during the mRNA splicing process. This targeted exclusion, or "exon skipping," is intended to enable the production of a shortened but still functional form of the dystrophin protein, thereby potentially preserving muscle function. This mechanism is a key aspect of SRP-5051's therapeutic strategy, aiming to better prompt exon-skipping and dystrophin production.

The development of SRP-5051 builds upon Sarepta's established exon-skipping technology. Compared to earlier therapies like eteplirsen, SRP-5051 incorporates a peptide conjugation strategy. This peptide is designed to enhance the ability of the exon-skipping agent to penetrate cells, potentially leading to improved efficacy and allowing for less frequent dosing. Research in preclinical models, such as a disease-relevant, humanized mouse model of DMD, demonstrated that a single dose of SRP-5051 could result in sustained exon 51 skipping.

Clinical trials have been central to evaluating the safety and efficacy of SRP-5051. The Two-Part Study for Dose Determination of Vesleteplirsen (SRP-5051), also referred to by its clinical trial identifier NCT04004065, was designed to assess different dosages and then evaluate efficacy. The MOMENTUM trial, specifically investigating SRP-5051 (vesleteplirsen), enrolled male patients aged 8 to 21 years with amenable mutations. Early data from the MOMENTUM trial, particularly Part A, indicated that SRP-5051 increases exon skipping and dystrophin production. For instance, SRP-5051 dosed monthly at 30 mg/kg delivered mean exon skipping of 10.79% and mean dystrophin expression of 6.55%, which were reported as consistently higher than other SRP-5051 treatment groups and compared favorably to eteplirsen. These findings suggested that SRP-5051 could offer a more potent therapeutic effect.

However, the journey of SRP-5051 has also been marked by significant challenges. In June 2022, the U.S. Food and Drug Administration (FDA) placed a clinical hold on the DMD drug candidate SRP-5051 due to a serious adverse event of hypomagnesemia. This hold temporarily halted further clinical testing. Subsequently, in September 2022, the FDA lifted this hold, allowing clinical trials to resume. Despite promising Phase 2 results in dystrophin expression and exon skipping, Sarepta Therapeutics announced in November 2024 the discontinuation of SRP-5051 development. This decision was attributed to safety concerns, leading to the cessation of the MOMENTUM study. The company's decision to stop developing SRP-5051, a potential treatment for Duchenne Muscular Dystrophy, marked a significant turning point in its investigational path.

The development of SRP-5051 represents a strategic exploration into higher efficacy and improved intracellular uptake through peptide conjugation. While SRP-5051 was designed to bind to exon 51 and enable DMD patients to produce a form of the dystrophin protein, similar to Sarepta's Exondys 51, its pathway was ultimately impacted by safety considerations. It is important to note that SRP-5051 PPMO is investigational and has not been reviewed or approved by any regulatory authority for widespread use. The scientific community continues to learn from these trials, contributing valuable data to the ongoing efforts to find effective treatments for Duchenne Muscular Dystrophy and other genetic disorders. The research into vesleteplirsen (SRP-5051), even with its